Global Biodefense June 28, 2022 A team of researchers in the US (NIAID, industry) has demonstrated that an inactivated, multivalent whole virus vaccine, delivered intramuscularly or intranasally, is broadly protective against challenges with multiple IAV HA/NA subtypes in both mice and ferrets, including challenges with IAV subtypes not contained in the vaccine. This vaccine approach indicates the feasibility of eliciting broad “universal” IAV protection and identifies a promising candidate for influenza vaccine clinical development…read more. Open Access TECHNICAL ARTICLE
Tag Archives: Broad spectrum vaccine
Nanoparticle vaccine protects against a spectrum of COVID-19-causing variants and related viruses
Phys.org July 5, 2022 An international team of researchers (USA – Caltech, NIAID, University of Washington, Stanford, industry, the Rockefeller University, UK) chose eight different SARS-like betacoronaviruses—including SARS-CoV-2 along with seven related animal viruses that could have potential to start a pandemic in humans—and attached fragments from those eight viruses onto the nanoparticle scaffold. The idea was that such a vaccine could induce the body to produce antibodies that broadly recognize SARS-like betacoronaviruses to fight off variants in addition to those presented on the nanoparticle by targeting common characteristics of viral RBDs. In mice, antibodies to the SARS-CoV-2 RBD were […]
New study boosts hope for a broad vaccine to combat COVID-19 variants and future coronavirus outbreaks
Science Daily August 19, 2021 Researchers in Singapore have provided data showing that potent cross-clade pan-sarbecovirus neutralizing antibodies are induced in survivors of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) infection who have been immunized with the BNT162b2 messenger RNA (mRNA) vaccine. The antibodies are high-level and broad-spectrum, capable of neutralizing not only known variants of concern but also sarbecoviruses that have been identified in bats and pangolins and have the potential to cause human infection. These findings show the feasibility of a pan-sarbecovirus vaccine strategy…read more. Open Access TECHNICAL ARTICLE
Intranasal influenza vaccine enhances immune response and offers broad protection
Science Daily May 3, 2021 Soluble protein vaccines are poorly immunogenic if administered by an intranasal route. A team of researchers in the US (Georgia State University, Emory University) developed an intranasal influenza vaccine using recombinant hemagglutinin (HA), a protein found on the surface of influenza viruses, as the antigen component of the vaccine. HA is integral to the ability of influenza virus to cause infection. They also created a two-dimensional nanomaterial (polyethyleneimine-functionalized graphene oxide nanoparticles) and found that it displayed potent immunoenhancing effects on influenza vaccines delivered intranasally. The study, conducted in mice and cell culture, found the nanoparticles significantly […]